This product is a high-purity (>98%) and highly active multipotent hematopoietic growth factor. RhGM CSF can specifically promote the differentiation of hematopoietic progenitor cells into granulocytes and macrophages. In immunological research, it is a core factor that induces the transformation of monocytes into dendritic cells (DCs) in vitro, and is a reagent for constructing antigen presentation models and developing tumor vaccines. The product has been validated for activity through TF-1 cell proliferation experiments, with extremely low endotoxin levels (<0.1 EU/μ g) and excellent batch stability, supporting immune cell therapy and basic medical research.